Menu

NJII Directors Dr. Haro Hartounian and Tomas Gregorio  Named to NJBIZ 2018 Vanguard Series Honor Roll

NJII Directors Dr. Haro Hartounian and Tomas Gregorio Named to NJBIZ 2018 Vanguard Series Honor Roll

by admin, January 3, 2019

NJII Executive Director, Biotechnology & Pharmaceutical Innovation, Dr. Haro Hartounian and NJII Sr. Executive Director, Healthcare Systems Innovation, Tomas Gregorio have been named to the NJBIZ Vanguard Series Leaders in Health Care Honor Roll for 2018.

 

Dr. Haro Hartounian is leading the creation of NJII’s Cell and Gene Therapy Development Center scheduled to open in 2019. Among other projects, the center will be undertaking the manufacturing process for new T cell cancer treatments on behalf of major biopharma companies and medical centers. With more than 240 immuno-oncology treatments in development, the demand for manufacturing facilities is predicted to be intense in order to meet the needs of patients. NJII is already training biopharmaceutical employees and new hires in the disciplines prerequisite to undertaking advanced cell and gene therapy manufacturing processes.

 

In leading NJII’s Healthcare Delivery Systems iLab, Tomas Gregorio’s team has completed the third year of its four-year project for the Centers for Medicare and Medicaid, in which it took data from 10,000 physicians nationwide and identified $120 million in cost savings. Gregorio is also leading the development of the New Jersey Health Information Network, a project that studies ways in which to cut waste in the state’s health care industry by identifying each of the state’s 9.5 million residents with a unique number so each doctor anywhere in the U.S. will be ble to access an individual’s health information. The network is expected to be fully operational within two years.